KBI-BIOPHARMA
KBI Biopharma SA (KBI) and Selexis SA, both JSR Life Sciences companies, held a joint ribbon-cutting ceremony yesterday at their new state-of-the-art facility in Geneva, Switzerland. Designed to directly serve the increased demand for biopharmaceutical drug development and manufacturing in Europe, the facility will support an integrated, end-to-end process of Selexis’ cell line development (CLD) services along with KBI’s contract development and manufacturing services for industry clients throughout the immediate region and beyond.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220706005082/en/
As demand for innovative biologics and effective biosimilars to treat cancer, infectious diseases, and autoimmune diseases continue to rise in Europe and around the world, developing and manufacturing these and other therapeutics, remains complex and time-consuming. By co-locating in one facility, KBI and Selexis will deliver trusted, streamlined, and cost-effective solutions to help clients confidently advance their investigational therapies.
“The opening of our Geneva facility last month was a major milestone for KBI and Selexis, and we are excited to come together today and commemorate this great achievement,” said Mark W. Womack, CEO of KBI and Selexis. “KBI and Selexis have a long history of success together. Our collaboration has accelerated more than 60 drug development programs in Europe and worldwide. Integrating Selexis’ world-renowned CLD services with KBI’s process development innovation and excellence, as well as clinical and commercial manufacturing experience provides our clients with seamless, cost-effective, and reliable development and manufacturing for their products. Our aim has always been to help our clients bring novel and effective therapies to the clinic and the market faster. This facility will help advance that mission.”
The ~94,000 square-foot facility will house new laboratories to support Selexis’ unique technical cell line workflows and KBI’s process development and cGMP manufacturing and quality control with a suite of analytical testing laboratories and cGMP single-use manufacturing trains. The expansion will generate over 300 positions in development, operations, and quality assurance. The ribbon-cutting, held on July 5, was attended by the following:
- Luca Bolliger, VP of the Swiss Biotech Association and President of the Swiss Biotech Success Stories Jury
- Mario Rodriguez, Mayor of Plan-les-Ouates
- Fabienne Fischer, State Councilor - Member of the Geneva government, Head of the economy and employment department (DEE)
“I am delighted with the development of KBI and Selexis' activities in Geneva, which contributes to the development of the life sciences sector in Geneva and reinforces our local ecosystem,” said Councilor Fischer. “It also demonstrates the potential and attractiveness of our region.”
About KBI Biopharma, Inc.
KBI Biopharma SA is a wholly-owned subsidiary of KBI Biopharma, Inc., and a JSR Life Sciences company. KBI Biopharma is a leading global contract development and manufacturing organization (CDMO) providing fully integrated, accelerated drug development and biologics manufacturing services and expertise to life science companies. With each of its 500+ client partners, KBI works closely to personalize and accelerate drug development programs. Built upon a foundation of world-class analytics capabilities and extensive scientific and technical expertise, KBI delivers robust process development and clinical and commercial cGMP manufacturing services for mammalian, microbial, and cell therapy programs. Recognized for quality manufacturing, KBI helps clients advance drug candidates into the clinic and beyond. KBI serves its global clients with multiple locations in Europe and the USA. www.kbibiopharma.com
About Selexis SA
Selexis SA, a JSR Life Sciences company, is the global leader in cell line development with best-in-class modular technology and highly specialized solutions that enable the life sciences industry to rapidly discover, develop and commercialize innovative medicines and vaccines. Our global client partners have utilized Selexis technologies to advance more than 160 drug candidates in preclinical and clinical development and manufacture ten commercial products. As part of a comprehensive drug development process, the Company’s technologies shorten development timelines and reduce manufacturing risks. More information is available at www.selexis.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20220706005082/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Comera Financial Holdings, Part of Abu Dhabi’s Royal Group, and SC Ventures Announce Strategic Collaboration to Explore Innovation in SME and Beyond23.12.2025 06:05:00 CET | Press release
Collaboration aims to co-create data-driven financial solutions, expand access to SME financing, and accelerate corporate innovation across the UAE’s evolving economic landscape. Comera Financial Holdings, part of Abu Dhabi’s Royal Group, and SC Ventures signed an MoU announcing a strategic collaboration to jointly explore new opportunities designed to strengthen the SME segment. The initiative reflects a shared vision to advance technology-driven financial solutions that align with the UAE’s economic priorities and support sustainable development across key sectors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251222001568/en/ Akhtar Saeed Hashmi, Managing Director & Group CEO of Comera Financial Holdings, and Alex Manson, CEO of Standard Chartered Ventures, sign an MoU announcing a strategic collaboration. (Photo: AETOSWire) Through this collaboration, Comera Financial Holdings and SCV have outlined several areas where t
Lattice to Showcase its Latest FPGA Technology Innovations at the International VLSID Conference23.12.2025 01:50:00 CET | Press release
‒ Pravin Desale, Head of R&D, to Deliver Keynote on Growing Need for Low Power FPGAs ‒‒ Multiple Technical Sessions Focused on Edge AI, Sensor Fusion, System Design, and More ‒ Lattice Semiconductor (NASDAQ: LSCC), the low power programmable leader, today announced its exhibition plan for the upcoming International VLSID Conference taking place January 3 – 7, 2026 in Pune, India. As part of the event, Lattice Senior Vice President of Research and Development Pravin Desale will deliver a keynote presentation exploring the market dynamics and trends that are positioning low power FPGAs at the forefront of technological advancements. Lattice will also have track sessions and panel discussions on low power FPGAs and AI from edge to cloud, and technology demonstrations with industry partners focused on advanced automotive and robotics applications. Who: Lattice Semiconductor What / When (GMT+2): Lattice Demo Showcase (Major Stall #B1), Jan 5 – 7 Keynote Jan. 5, 10:30 – 11 a.m. at Main Audit
First Cessna SkyCourier Delivered into Mexico, Expanding Air Freight Capabilities for FlexCoah22.12.2025 18:13:00 CET | Press release
The first Cessna SkyCourier in Mexico was recently delivered to cargo transportation provider FlexCoah for use by the company’s aviation subsidiary, Altair. The aircraft — a freighter variant — will expand the company’s air freight capabilities throughout the country. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251222890759/en/ First Cessna SkyCourier delivered into Mexico, expanding air freight capabilities for FlexCoah (Photo Credit: Textron Aviation) The Cessna SkyCourier is designed and manufactured by Textron Aviation Inc., a Textron Inc. (NYSE: TXT) company. “The Cessna SkyCourier’s combination of reliability, payload capacity and mission flexibility makes it a powerful asset for operators looking to scale their operations while maintaining cost-efficiency,” said Lannie O’Bannion, senior vice president, Sales & Marketing. “The delivery of the Cessna SkyCourier to FlexCoah reflects the aircraft’s growing role in tran
Proudly Produced in Donegal: ProAmpac Invests in the Future of Food Board Manufacturing22.12.2025 17:34:00 CET | Press release
ProAmpac, a global leader in flexible packaging and material science, is strengthening its operational footprint with the expansion of Food Board manufacturing capabilities at its Donegal, Ireland campus. The addition of a new, purpose-built Food Board production area within the existing site reinforces ProAmpac’s commitment to innovation, efficiency, and customer service across the food packaging sector. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251222149380/en/ Carr & Sons Smoked Salmon - ProAmpac As an extension of the existing Donegal operations, which support the pet food, food-to-go, and CPG markets, the expanded production area increases capacity and precision. A state-of-the-art guillotine system delivers cleaner cuts and consistent board quality, ensuring every sheet meets ProAmpac’s performance standards. The expanded facility area introduces several key improvements for customers: Dedicated Customer Service T
Coherent Solutions closes strategic investment led by IceLake22.12.2025 16:07:00 CET | Press release
Coherent Solutions, a global digital engineering firm, has announced the closing of the strategic investment from IceLake, a leading private equity investor specializing in partnering with high-growth business services organizations. The transaction, previously announced in September 2025, has now received all necessary regulatory approvals. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251222791182/en/ Coherent Solutions and IceLake close strategic investment Coherent Solutions employs ~2,000 digital engineering, product, and design professionals across Europe and Latin America. The company builds and modernizes digital products and platforms for growing scale-ups and established global brands. “In a market saturated with AI claims, we’re seeing clients prioritize partners who can convert technology into measurable business outcomes,” said Igor Epshteyn, CEO of Coherent Solutions. “Staying grounded in digital value creatio
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom